Progress in neuro-psychopharmacology & biological psychiatry
April 2, 2025
Simon Reiche, Tim Hirschfeld, Anna Lena Gröticke et al.
5 citations
People who have used psychedelics such as psilocybin, LSD, or ayahuasca a mild to moderate number of times over their lives show broadly equivalent neuropsychological performance to non-users, but with a modest advantage in executive functions, particularly cognitive flexibility as measured by the Wisconsin Card Sorting Test (WCST). In matched-pair analyses, users performed better on the WCST, and dose-response analyses within the user group found that greater lifetime use was positively associated with fewer total errors, perseverative responses, perseverative errors, non-perseverative errors, and more conceptual level responses. The study did not find any negative associations between sporadic psychedelic use and cognition.
Scientific Reports
December 31, 2024
Georg Leistenschneider, Tomislav Majić, Simon Reiche et al.
3 citations
Classic psychedelics like LSD and psilocybin show promise for treating psychiatric disorders but can occasionally cause lasting psychological harm, including Hallucinogen Persisting Perception Disorder (HPPD), a rare condition with enduring perceptual symptoms. This study examined the neuropsychological profiles of eight individuals with HPPD using a comprehensive test battery, comparing their performance against normative data and two matched control groups (with and without prior psychedelic use). Some participants with HPPD scored below average on tests of visual memory and executive function. Statistically adjusted comparisons found no significant differences between groups, though unadjusted analyses hinted at impaired executive functions in HPPD patients. These preliminary findings highlight the need for more focused research on the neuropsychological aspects of HPPD.
medRxiv Preprint Server
May 23, 2026
Lisa Maria Jöbstl, Bente Lubahn, Ebru Kaya et al.
preprint
A subset of individuals who use classic psychedelics outside clinical settings reports persisting adverse effects, including hallucinogen persisting perception disorder, depersonalization/derealization disorder, anxiety, and depression. Despite growing non-clinical use, few medical services are equipped to address these complications. The authors highlight a delay in attention to these persisting adverse effects relative to enthusiasm for therapeutic potential.